3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
45
Gynecologic
2
Other
1
Head & Neck
1
Conditions
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Breast Diseases
1
Interventions
Cisplatin
85
pembrolizumab
76
Magnetic Resonance Spectroscopy
46
Radiotherapy, Intensity-Modulated
41
Specimen Handling
36
Cetuximab
36
Carboplatin
35
Radiotherapy
34
Nivolumab
28
Paclitaxel
24
Radiation
22
Platinum
22
Docetaxel
20
Biopsy
20
1,2-diaminocyclohexaneplatinum II citrate
20
Gemcitabine
19
Surveys and Questionnaires
15
Fluorouracil
14
toripalimab
13
Standard of Care
12
Taxes
11
cemiplimab
9
atezolizumab
9
Ipilimumab
9
Drug Therapy
9
Cyclophosphamide
9
X-Rays
8
Surgical Procedures, Operative
8
Radiosurgery
7
Immunoglobulin G
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Anastrozole
×
Head & Neck
×
90 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled